Rationale for Anti-angiogenic Therapy in Pheochromocytoma and Paraganglioma
Judith Favier(Inserm), Anne‐Paule Gimenez‐Roqueplo(Délégation Paris 5), Cécile Badoual(Inserm), Xavier Jeunemaı̂tre(Délégation Paris 5), Rossella Libé(Hôpital Cochin), Péter Igaz(Semmelweis University), Nelly Burnichon(Inserm), Laurence Amar(Unit of Functional and Adaptive Biology), Pierre-François Plouin(Délégation Paris 5), Frédérique Tissier(Sorbonne Université), Jérôme Bertherat(Centre National de la Recherche Scientifique)
Cited by 91
Related Papers
The 2017 international classification of the Ehlers–Danlos syndromes
|American Journal of Medical Genetics Part C Seminars in Medical Genetics|2017|1.9k
The ratio of the nucleon structure functions F2N for iron and deuterium
|Physics Letters B|1983|1.1k
Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort
|The Lancet Diabetes & Endocrinology|2017|951
Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma
|Cancer Cell|2017|791